New treatment for dry eye syndrome
New treatment for dry eye syndrome
2008-04-09Newsfeed
An ophthalmic pharmaceutical firm has launched a new product to treat dry eye syndrome.
An ophthalmic pharmaceutical firm has launched a new product to treat dry eye syndrome.
Cationorm(R), a cationic emulsion which reproduces the tear mechanism of action to act of the different levels of tear film, has been launched by Novagali Pharma.
It has been developed on the basis of Novagali Pharma patented technology platform Novasorb(R).
Dry eye syndrome is the second cause of consultation in ophthalmology and affects more than 100 million people worldwide.
The condition occurs due to a lack of lubrication and moisture in the eye which results in irritation to ocular inflammation of the conjunctiva and corneal tissues of the eyes.
Sufferers endure a sandy-gritty irritation or burning in their eyes. In more severe cases, corneal lesions may lead to vision loss.
Factors such as ageing populations, pollution, air conditioning, extended use of computers, contribute to an increase in the prevalence of the syndrome.
Copyright © The Press Association 2008
